Shots:

• The P-II/III study involves assessing of CT-P59 (40mg/kg- 80mg/kg) vs PBO in 327 patients with mild-to-mod. symptoms of COVID-19
• Results: reduction in progression rates (54% for mild-to-mod. patients & 68% for mod. patients aged ≥50yrs.); recovery days (5.4 vs 8.8 days); recovery time in patients with pneumonia & patients aged ≥50yrs. (5.7 vs 10.8 & 6.6 vs 13days) respectively. CT-P59 showed reduction in viral load @day7 with SAEs reported
• The preclinical data demonstrated a 100-fold reduction in viral load of SARS-CoV-2 and improved recovery time in animal models- that has been published in Nature Communications journal

 ­ Ref: Businesswire | Image: Celltrion